Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 12/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806284 | 0.86 | KDM4E (0.37) | CYP11B2CYP11B1XDH | |
| SCHEMBL17806283 | 0.86 | USP30 (0.34) | CYP11B2CYP11B1 | |
| SCHEMBL17809672 | 0.85 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP3A4CYP19A1FGFR4 | |
| SCHEMBL17806288 | 0.84 | GPR119 (0.40) | CYP11B2CYP11B1 | |
| SCHEMBL17806323 | 0.83 | CYP11B2 (0.38) | CYP11B2CYP11B1 | |
| SCHEMBL17806318 | 0.82 | CYP11B2 (0.39) | CYP11B2CYP11B1HTR2AHTR2C | |
| SCHEMBL17806385 | 0.82 | CYP11B2 (0.37) | CYP11B2CYP11B1HTR2AHTR2C | |
| SCHEMBL17806374 | 0.82 | CYP11B2 (0.39) | CYP11B2CYP11B1 | |
| SCHEMBL17806375 | 0.80 | EED (0.34) | CYP11B2CYP11B1 | |
| SCHEMBL17806346 | 0.80 | WNT3A (0.39) | CYP11B2CYP11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | CYP11B2 1605/4885CYP11B1 1468/4885CYP3A4 3799/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | CYP11B2 1605/4885CYP11B1 1468/4885CYP3A4 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.